All In Biotech

Drug Trial Radar · NCT05216887

A Study to Assess the Pharmacokinetic (PK) Comparability of 2 Fixed Subcutaneous (SC) Doses of Aducanumab (BIIB037) With a Single, Weight-Based Intravenous (IV) Dose in Healthy Volunteers

A Randomized, Open-Label, Parallel-Arm Study to Assess the Pharmacokinetic Comparability of 2 Fixed Subcutaneous Doses of Aducanumab (BIIB037) With a Single, Weight-Based Intravenous Dose in Healthy Volunteers

Last checked: Nov 20, 2026Latest source record: Apr 18, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 123 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

123

Actual

Start

Feb 1, 2022

Primary completion

Jul 27, 2022

Study completion Jul 27, 2022

Sponsor

Lead sponsor
BiogenBiogen (BIIB)
Sponsor type
Industry
First posted
Feb 1, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 40 years, up to 70 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The primary objective of the study is to evaluate the pharmacokinetic (PK) comparability of 2 fixed subcutaneous (SC) doses of aducanumab with a single, weight-based intravenous (IV) dose of aducanumab in healthy volunteers. The secondary objectives of the study are to assess the safety and tolerability of aducanumab administered SC in healthy volunteers and to characterize additional PK parameters of 2 fixed SC doses of aducanumab and a single, weight-based IV dose of aducanumab.

Conditions

  • Healthy Volunteer

Interventions

  • AducanumabBiological

    Administered as specified in the treatment arm.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Area Under the Concentration-Time Curve From Time 0 to Infinity (AUCinf) of AducanumabTime frame: Predose and at multiple time points post-dose up to Day 99

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Anaheim Clinical Trials

    Anaheim, California

  • QPS-MRA

    Miami, Florida

  • QPS Missouri

    Springfield, Missouri

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.